步长制药
(603858)
| 流通市值：156.50亿 | | | 总市值：156.50亿 |
| 流通股本：10.55亿 | | | 总股本：10.55亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 8,017,382,205.31 | 5,003,092,046.35 | 2,579,013,525.28 | 11,875,013,010.12 |
| 营业收入 | 8,017,382,205.31 | 5,003,092,046.35 | 2,579,013,525.28 | 11,875,013,010.12 |
| 二、营业总成本 | 7,028,612,129.41 | 4,365,535,951.93 | 2,180,656,976.18 | 10,600,810,736.07 |
| 营业成本 | 3,196,856,213.76 | 1,941,873,660.52 | 945,267,292.76 | 4,399,990,372.09 |
| 税金及附加 | 119,077,085.92 | 73,893,276.14 | 38,530,950.52 | 176,006,501.14 |
| 销售费用 | 2,840,173,783.65 | 1,809,408,720.44 | 946,410,381.21 | 4,828,332,232.54 |
| 管理费用 | 611,738,644.02 | 375,509,285.06 | 179,721,159.7 | 843,025,161.72 |
| 研发费用 | 172,952,448.8 | 107,295,165.42 | 42,834,669.61 | 240,102,458.57 |
| 财务费用 | 87,813,953.26 | 57,555,844.35 | 27,892,522.38 | 113,354,010.01 |
| 其中:利息费用 | 89,092,465.05 | 58,484,583.55 | 28,722,255.25 | 118,700,545.2 |
| 其中:利息收入 | 2,605,755.76 | 1,742,265.07 | 786,691.73 | 4,836,847.23 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -26,567,280.7 | -21,862,922.75 | -2,396,282.88 | -279,493,363.52 |
| 加:投资收益 | -40,607,731.8 | -24,748,867.49 | -17,905,331.12 | -3,840,753.16 |
| 资产处置收益 | 227,775.83 | 109,725.39 | 285,576.44 | 156,484.37 |
| 资产减值损失(新) | -9,384,716.03 | -4,821,480.06 | 662,841.55 | -527,219,503.79 |
| 信用减值损失(新) | 858,511.16 | 857,695.04 | -7,135,038.07 | 14,347,948.32 |
| 其他收益 | 48,779,714.79 | 26,785,543.3 | 13,957,474.39 | 87,955,649.28 |
| 四、营业利润 | 962,076,349.15 | 613,875,787.85 | 385,825,789.41 | 566,108,735.55 |
| 加:营业外收入 | 4,837,265.2 | 3,565,037.96 | 702,824.28 | 4,967,765.31 |
| 减:营业外支出 | 25,923,362.32 | 14,569,826.49 | 3,947,193.54 | 37,121,029.15 |
| 五、利润总额 | 940,990,252.03 | 602,870,999.32 | 382,581,420.15 | 533,955,471.71 |
| 减:所得税费用 | 217,050,594.5 | 141,045,451.52 | 79,478,670.97 | 341,657,918.23 |
| 六、净利润 | 723,939,657.53 | 461,825,547.8 | 303,102,749.18 | 192,297,553.48 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 723,939,657.53 | 461,825,547.8 | 303,102,749.18 | 192,297,553.48 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 789,367,785.23 | 502,585,589.91 | 320,411,354.85 | 360,784,856.21 |
| 少数股东损益 | -65,428,127.7 | -40,760,042.11 | -17,308,605.67 | -168,487,302.73 |
| 扣除非经常损益后的净利润 | 806,704,600.09 | 509,074,766.5 | 310,186,180.17 | 634,750,809.03 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.75 | 0.48 | 0.3 | 0.34 |
| (二)稀释每股收益 | 0.75 | 0.48 | 0.3 | 0.34 |
| 八、其他综合收益 | 1,009,503.09 | -679,343.46 | 6,756,134.75 | -53,165,050.17 |
| 归属于母公司股东的其他综合收益 | 1,009,503.09 | -679,343.46 | 6,756,134.75 | -53,165,050.17 |
| 九、综合收益总额 | 724,949,160.62 | 461,146,204.34 | 309,858,883.93 | 139,132,503.31 |
| 归属于母公司股东的综合收益总额 | 790,377,288.32 | 501,906,246.45 | 327,167,489.6 | 307,619,806.04 |
| 归属于少数股东的综合收益总额 | -65,428,127.7 | -40,760,042.11 | -17,308,605.67 | -168,487,302.73 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-28 | 2026-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |